LANGE LOUIS G
SEC Form 4 insider trading activity
LANGE LOUIS G has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Mar 12, 2026.
On the most recent filing, LANGE LOUIS G is listed as Director at NewAmsterdam Pharma Co N.V. Inside the rolling window, LANGE LOUIS G reported no open-market purchases and 2 open-market sales totaling $2.2M in NAMS. The largest disclosed transaction in the window is a sale of 44,619 NAMS shares on Mar 11, 2026, worth $1.4M.
Companies traded
Other insiders at NAMS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has LANGE LOUIS G made?
LANGE LOUIS G has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does LANGE LOUIS G trade?
LANGE LOUIS G has filed SEC Form 4 disclosures for 1 company, including NAMS.
When was LANGE LOUIS G's most recent SEC Form 4 filing?
LANGE LOUIS G's most recent SEC Form 4 filing on Tracefour is dated Mar 12, 2026.
What is LANGE LOUIS G's total buy and sell value in the current window?
Inside the rolling retention window, LANGE LOUIS G bought $0 and sold $2.2M based on SEC Form 4 filings.
What was LANGE LOUIS G's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 44,619 NAMS shares on 2026-03-11, worth $1.4M, per SEC Form 4 filings.